{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Laskow T"],"funding":["Johns Hopkins Older Americans Independence Center","NIA NIH HHS","Salisbury Family Foundation","National Institute on Aging"],"pubmed_abstract":["<h4>Background</h4>Chronic inflammation (CI) is a common trait of aging associated with adverse outcomes including mortality. We hypothesized that recombinant human Lactoferrin (rhLf) would reduce chronic inflammation of aging.<h4>Methods</h4>Thirty-six community dwelling older adults were randomly assigned to rhLf or placebo treatment in 1:1 ratio for 3 months. IL-6, sTNFR1, Comprehensive Metabolic Panel (CMP), and Complete Blood Count (CBC) were measured at baseline, 1 month, 3 months, and 6 months. Physical and cognitive measures were completed at same timepoints, including 4-m walking speed (m/s), grip strength (kg), 6-min walking distance (m), home activity measured by accelerometer, trail making test - Part A (s) and - Part B (s), and Digit symbol substitution test (number correctly "],"journal":["Physiology international"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9211386"],"repository":["biostudies-literature"],"pubmed_title":["Lactoferrin for the treatment of age-associated inflammation - A pilot study."],"pmcid":["PMC9211386"],"funding_grant_id":["P30 AG021334","R21 AG053681","P30 AG024827","T32 AG058527"],"pubmed_authors":["Laskow T","Walston J","Langdon J","Abadir P","Xue QL"],"additional_accession":[]},"is_claimable":false,"name":"Lactoferrin for the treatment of age-associated inflammation - A pilot study.","description":"<h4>Background</h4>Chronic inflammation (CI) is a common trait of aging associated with adverse outcomes including mortality. We hypothesized that recombinant human Lactoferrin (rhLf) would reduce chronic inflammation of aging.<h4>Methods</h4>Thirty-six community dwelling older adults were randomly assigned to rhLf or placebo treatment in 1:1 ratio for 3 months. IL-6, sTNFR1, Comprehensive Metabolic Panel (CMP), and Complete Blood Count (CBC) were measured at baseline, 1 month, 3 months, and 6 months. Physical and cognitive measures were completed at same timepoints, including 4-m walking speed (m/s), grip strength (kg), 6-min walking distance (m), home activity measured by accelerometer, trail making test - Part A (s) and - Part B (s), and Digit symbol substitution test (number correctly ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-09T10:49:45.103Z","creation":"2024-11-21T04:25:08.542Z"},"accession":"S-EPMC9211386","cross_references":{"pubmed":["33844642"],"doi":["10.1556/2060.2021.00010"]}}